The immunoscore is based on the quantification and localization of CD3+ and CD8+ lymphocytes within tumors and their invasive margin and evidence so far suggests that this alternative scoring system is a more robust classification system for CRC for predicting survival than the classical tumor-node-metastasis staging system (81, 82). The gene discussed is CD8A; the disease is neoplasm.